Completed PHASE1 INTERVENTIONAL 1-arm NCT02418624

Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer (REVIVAL)

A Phase I Followed by a Randomized Phase II Trial of Two Cycles Carboplatin-Olaparib Followed by Olaparib Monotherapy Versus Capecitabine in BRCA-1 or -2 Mutated Her2 Negative Advanced Breast Cancer as First Line Treatment

Sponsor: The Netherlands Cancer Institute

Conditions Advanced Cancer Breast Cancer Ovarian Cancer

Interventions carboplatin, olaparib

Updated 7 times since 2017 Last updated: Jan 14, 2019 Started: May 31, 2015 Primary completion: Jan 31, 2019 Completion: Jan 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Cancer and Breast Cancer and is currently completed. The Netherlands Cancer Institute leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Unknown Status → Completed
Jun 2018 — Feb 2019 [monthly]

Unknown Status PHASE1

▶ Show 2 earlier versions

Feb 2018 — Jun 2018 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jan 2017 — Feb 2018 [monthly]

Recruiting PHASE1

First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Netherlands Cancer Institute

Data source: The Netherlands Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Amsterdam, Netherlands